News | April 03, 2022
JBCPL buys Azmarda trademark for India at Rs 246 crore
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
He has done his Masters in Pharmacy (M. Pharm) and Post Graduate Diploma in Personnel Management & Industrial Relations
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
An estimated 21 million American women experience BV
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
Subscribe To Our Newsletter & Stay Updated
